Adjunctive lacosamide in clinical practice: Sodium blockade with a difference?

Epilepsy and Behavior

Volumn 22, Issue 3, 2011, Pages 499-504

  Stephen, Linda J ^a   Kelly, Kevin ^a   Parker, Pamela ^a   Brodie, Martin J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Antiepileptic drug; Epilepsy; Lacosamide; Sodium blockade

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; HARKOSERIDE; LAMOTRIGINE; PHENOBARBITAL; PREGABALIN; VALPROIC ACID;

ADULT; AGED; AGITATION; ARTICLE; ATAXIA; CLINICAL PRACTICE; CONTROLLED STUDY; DIPLOPIA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; NEUROTOXICITY; PARTIAL ONSET SEIZURE; PROSPECTIVE STUDY; SEDATION; SEIZURE; SIDE EFFECT; TREMOR; VOMITING;

ACETAMIDES; ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80055017701     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.07.035     Document Type: Article

References (30)

1. Beyreuther B.K., Freitag J., Heers C., Krebsfänger N., Scharfenecker U., Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007, 13:21-42.
2. Errington A.C., Stöhr T., Heers C., Lees G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008, 73:157-169.
3. Ben-Menachem E., Biton V., Jatuzis D., Abou-Khalil B., Doty P., Rudd G.D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007, 48:1308-1317.
4. Halasz P., Kalviainen R., Mazurkiewicz-Beldzinska M., et al. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009, 50:443-453.
5. Chung S.M., Sperling M., Biton V., et al. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010, 51:958-967. on behalf of the SP754 Study Group.
6. Shaibani A., Fares S., Salah S., et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain 2009, 10:818-828.
7. Von Elm E., Altman D., Pocock S.J., GØtzsche P.C., Vandenbroucke J.P. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Br Med J 2007, 335:806-808. for the STROBE Initiative.
8. Zwarenstein M., Treweek S., Gagnier J.J., et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. Br Med J 2008, 337:1223-1226.
9. Brodie M.J., Yuen A.W.C. Lamotrigine substitution study: evidence for synergism with sodium valproate?. Epilepsy Res 1997, 26:423-432. and the 105 Study Group.
10. Besag F.M., Berry D.J., Pool F., Newbery J.E., Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?. Epilepsia 1998, 39:183-187.
11. Barcs G., Walker E.G., Elger C.E., et al. Oxcarbazepine placebo-controlled, dose ranging trial in refractory partial epilepsy. Epilepsia 2000, 41:1597-1607.
12. Wong I.C., Mawer G.E., Sander J.W., Lhatoo S.D. A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. Epilepsia 2001, 42:1354-1358.
13. Sake J.K., Hebert D., Isojarvi, et al. A pooled analysis of lacosamide clinical data grouped by mechanisms of action of concomitant antiepileptic drugs. CNS Drugs 2010, 24:1055-1068.
14. Novy J., Patsalos P.N., Sander J., Sisodiya S.M. Lacosamide neurotoxicity with concomitant use of sodium channel-blocking antiepileptic drugs: A pharmacodynamic interaction?. Epilepsy Behav 2011, 20:20-23.
15. Wehner T., Bauer S., Hamer H.M., et al. Six months of postmarketing experience with adjunctive lacosmide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009, 16:423-425.
16. Brodie M.J., Sills G.J. Combining antiepileptic drugs: rational polytherapy?. Seizure 2011, 20:369-375.
17. Shandra A., Shandra P., Kaschenko O., Stoehr T. Synergism of lacosamide with established antiepileptic drugs in the 6-Hz seizure model in mice. Presented at: 8th European Congress of Epileptology, Berlin 2008, Abstract T213.
18. Stephen L.J., Kelly K., Wilson E.A., Parker P., Brodie M.J. A prospective audit of adjunctive zonisamide in an everyday clinical setting. Epilepsy Behav 2010, 17:455-460.
19. Brodie MJ, Barry SJ, Bamagous GA, Norrie, JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology, submitted.
20. Chung W.H., Hung S.I., Hong H.S., et al. Medical genetics: a marker for Stevens Johnson syndrome. Nature 2004, 428:486.
21. Man C.B., Kwan P., Baum L., et al. Association between HLA-B* 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007, 48:1015-1018.
22. Chen P., Lin J.-J., Lu C.-S., et al. Carbamazepine-induced toxic effects and HLA-B* 1502 screening in Taiwan. N Engl J Med 2011, 364:1126-1133.
23. Ozeki T., Mushiroda T., Yowang A., et al. Genome-wide association study identifies HLA-A* 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions. Hum Mol Genet 2011, 20:1034-1041.
24. McCormack M., Alfirevic A., Bourgeois S., et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011, 364:1134-1143.
25. WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD index 2011. [Last updated 17/12/2009, cited July 2011]. Available from:. http://www.whocc.no/atc_ddd_index/.
26. Löscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 1999, 58:31-59.
27. Zona C., Avoli M. Effects induced by the antiepileptic drug valproic acid upon the ionic currents recorded in rat neocortical neurons in cell culture. Exp Brain Res 1990, 81:313-317.
28. Berg R.J., Kok P., Voskuyl R.A. Valproate and sodium currents in cultured hippocampal neurons. Exp Brain Res 1993, 93:279-283.
29. + current in neocortical neurons. Epilepsy Res 1998, 32:304-308.
30. White H.S., Rho J.M. Voltage-dependent sodium channels. Mechanisms of action of antiepileptic drugs 2010, 43-58. Professional Communications Inc., West Islip, NY. H.S. White, J.M. Rho (Eds.).